Development of cancer cell-selective necrosis-inducing agents for cancer treatment

2017 Fiscal Year Final Research Report

• Project/Area Number: 15K14983
• Research Category: Grant-in-Aid for Challenging Exploratory Research
• Allocation Type: Multi-year Fund
• Research Field: Drug development chemistry
• Research Institution: Sojo University
• Principal Investigator: KUNIYASU Akihiko 崇城大学, 薬学部, 教授 (90241348)
• Co-Investigator(Kenkyū-buntansha): 村田 和義 生理学研究所, 脳機能計測・支援センター, 准教授 (20311201) ; 牧瀬 正樹 崇城大学, 薬学部, 准教授 (80433001)
• Research Collaborator: ARAP Wadih 米国ニューメキシコ大学, 医学部, 教授 ; PASQUALINI Renata 米国ニューメキシコ大学, 医学部, 教授
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: ネクローシス / ペプチドミメティクス / がん

Outline of Final Research Achievements

To assess therapeutical implications of the necrosis-inducing agents for cancer treatment, we developed a neuropilin-1 (NRP-1)-targeted hybrid peptide, which induces non-apoptotic cell death against lung and breast cancer cells. We determined that the mode of cell death induced with the peptide is similar to necrosis. siRNA knockdown of NRP-1 on A549 cells significantly reduced cytotoxicity of the hybrid peptide. Also, treatment of the hybrid peptide on A549 cells lead to the extracellular release of a necrotic marker protein high mobility group B-1. The peptides will be a useful tool for development of novel concept-based anti-tumor agents such as a necrosis-inducer.

Free Research Field

生体機能化学